Subgroups, treatment effects, and baseline risks: Some lessons from major cardiovascular trials
- 1 June 2000
- journal article
- review article
- Published by Elsevier in American Heart Journal
- Vol. 139 (6) , 952-961
- https://doi.org/10.1067/mhj.2000.106610
Abstract
No abstract availableKeywords
This publication has 73 references indexed in Scilit:
- The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart FailureNew England Journal of Medicine, 1996
- Comparison of intravenous urokinase plus heparin versus heparin alone in acute myocardial infarctionThe American Journal of Cardiology, 1991
- Subgroup analysis of clinical trialsThe American Journal of Cardiology, 1991
- Effect of verapamil on mortality and major events after acute myocardial infarction (The Danish Verapamil Infarction Trial II — DAVIT II)The American Journal of Cardiology, 1990
- The Effect of Diltiazem on Mortality and Reinfarction after Myocardial InfarctionNew England Journal of Medicine, 1988
- A Prospective Trial of Intravenous Streptokinase in Acute Myocardial Infarction (I.S.A.M.)New England Journal of Medicine, 1986
- Protective Effects of Aspirin against Acute Myocardial Infarction and Death in Men with Unstable AnginaNew England Journal of Medicine, 1983
- A Controlled Comparison of Aspirin and Oral Anticoagulants in Prevention of Death after Myocardial InfarctionNew England Journal of Medicine, 1982
- Timolol-Induced Reduction in Mortality and Reinfarction in Patients Surviving Acute Myocardial InfarctionNew England Journal of Medicine, 1981
- Sulfinpyrazone in the Prevention of Sudden Death after Myocardial InfarctionNew England Journal of Medicine, 1980